Chemical formula: C₆₃H₈₅N₈O₁₇⁺ Molecular mass: 1,225.603 g/mol PubChem compound: 78318119
Rezafungin selectively inhibits fungal 1,3-β-D-glucan synthase. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall which is not present in mammalian cells. Inhibition of 1,3-β-D-glucan synthesis results in rapid and concentration-dependent fungicidal activity in Candida species (spp.).
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J02AX08 | J Antiinfectives for systemic use → J02 Antimycotics for systemic use → J02A Antimycotics for systemic use → J02AX Other antimycotics for systemic use | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| REZZAYO Powder for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| REZZAYO Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Rezafungin is an active ingredient of these brands:
United States (US)
Austria (AT)
Croatia (HR)
Estonia (EE)
France (FR)
Ireland (IE)
Lithuania (LT)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
